High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma

Recent advances in plasma cell biology and molecularly-targeted therapy enable us to employ various types of drugs including immunomodulatory drugs, proteasome inhibitors, and immunotherapy. However, the optimal therapeutic strategies to introduce these drugs for heterogeneous patients with multiple...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Ibata, Soushi, Kobune, Masayoshi, Kikuchi, Shohei, Yoshida, Masahiro, Miura, Shogo, Horiguchi, Hiroto, Murase, Kazuyuki, Iyama, Satoshi, Takada, Kohichi, Miyanishi, Koji, Kato, Junji
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5982762/
https://ncbi.nlm.nih.gov/pubmed/29861858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25350
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares